Xenon Pharmaceuticals Inc. (XENE)
| Market Cap | 5.20B |
| Revenue (ttm) | 7.50M |
| Net Income (ttm) | -345.91M |
| Shares Out | 95.43M |
| EPS (ttm) | -4.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 729,151 |
| Open | 54.85 |
| Previous Close | 54.26 |
| Day's Range | 53.30 - 55.53 |
| 52-Week Range | 28.19 - 63.95 |
| Beta | 0.75 |
| Analysts | Strong Buy |
| Price Target | 68.55 (+25.71%) |
| Earnings Date | May 8, 2026 |
About XENE
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In a... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for XENE stock is "Strong Buy." The 12-month stock price target is $68.55, which is an increase of 25.71% from the latest price.
News
Xenon Pharmaceuticals Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
Azetukalner demonstrated best-in-class efficacy and rapid onset in phase III epilepsy trials, with long-term data showing sustained seizure reduction and strong safety. Expansion into psychiatry and pain indications is underway, supported by robust financials and a growing pipeline.
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
VANCOUVER, British Columbia and BOSTON, MA, April 19, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, ...
Xenon to Present at Upcoming Investor Conferences
VANCOUVER, British Columbia and BOSTON, MA, April 15, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, ...
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures Poster presentations also include long-te...
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
VANCOUVER, British Columbia and BOSTON, MA, March 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, ...
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
VANCOUVER, British Columbia and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clin...
Xenon Pharmaceuticals Announces Proposed Public Offering
VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, ...
Crude Oil Rises Around 4%; Xenon Pharmaceuticals Shares Surge
Shares of Xenon Pharmaceuticals Inc (NASDAQ:XENE) got a boost, surging 41% to $59.13 following the announcement of positive topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset...
Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) shares are up during Monday's premarket session following the announcement of positive topline results from the Phase 3 X-TOLE2 study of azetukalner in focal ...
Xenon Pharmaceuticals Transcript: Study result
The phase III X-TOLE2 study of AZK in focal onset seizures met its primary and key secondary endpoints, showing robust, dose-dependent efficacy and a favorable safety profile in a highly refractory population. AZK’s differentiated mechanism, ease of use, and consistent results position it for broad adoption and NDA submission in Q3.
Xenon Pharma's epilepsy drug meets main goal in late-stage trial
Xenon Pharmaceuticals said on Monday its experimental epilepsy drug met the main goal of a late-stage trial, showing a statistically significant reduction in focal onset seizures.
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, ...
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clin...
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
Phase 3 X-TOLE2 topline data for azetukalner in FOS expected first half of March 2026 Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and neuropsychiatry indications with...
Polarean Expands Xenon MRI Platform into Cardiopulmonary Drug Development with Multi-Center PH-ILD Study
Innovative Trial Design to Directly Measure Microvascular Functional Effects of Inhaled Therapy at the Capillary level of Pulmonary Hypertension Patients with Interstitial Lung Disease (PH-ILD) Innova...
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, British Columbia and BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clini...
Xenon Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
Azetukalner is advancing through six phase III trials in epilepsy and neuropsychiatry, with top-line data from the X-TOLE2 epilepsy study expected in March. Long-term data show robust efficacy and safety, while expansion into depression and pain indications is underway.
Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference
VANCOUVER, British Columbia and BOSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clini...
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
VANCOUVER, British Columbia and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clini...
Xenon Pharmaceuticals Transcript: Status Update
AZK continues to demonstrate strong, durable efficacy and safety in long-term studies, with significant seizure freedom rates and a favorable profile for both clinicians and patients. Commercial preparations are robust, leveraging AZK's unique attributes for broad adoption and addressing key unmet needs in epilepsy care.
Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025
VANCOUVER, British Columbia and BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clini...
Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025
VANCOUVER, British Columbia and BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clini...
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025
Seven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalner Data will also highlight ...
Xenon Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025
Azetukalner is advancing through multiple phase III trials in epilepsy and neuropsychiatry, with key data from the X-TOLE2 epilepsy study expected in early 2026 and NDA submission planned for later that year. The pain portfolio is progressing, with phase II proof-of-concept data targeted for 2027.
Xenon Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference
Azetukalner's phase III epilepsy data is expected in early 2026, with NDA filing planned next year. Psychiatry and pain programs advance with multiple phase III and phase I trials, while commercial launch preparations and strong cash reserves support growth.